UBS Group
CLLS

UBS Group’s Cellectis CLLS Stock Holding History

UBS Group’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.4K Sell
29,774
-20,326
-41% -$77.9K ﹤0.01% 7033
2025
Q4 		$242K Buy
50,100
+20,801
+71% +$86.9K ﹤0.01% 6479
2025
Q3 		$83.5K Buy
29,299
+3,670
+14% +$9.51K ﹤0.01% 7241
2025
Q2 		$39.1K Sell
25,629
-18,846
-42% -$27.2K ﹤0.01% 7972
2025
Q1 		$55.1K Sell
44,475
-184,606
-81% -$274K ﹤0.01% 7510
2024
Q4 		$412K Buy
+229,081
New +$427K ﹤0.01% 5981
2024
Q1 		– Sell
-100
Closed -$308 – 9392
2023
Q4 		$308 Sell
100
-3,935
-98% -$9.34K ﹤0.01% 8736
2023
Q3 		$6.38K Buy
+4,035
New +$7.88K ﹤0.01% 7304
2023
Q2 		– Sell
-330
Closed -$637 – 8998
2023
Q1 		$637 Sell
330
-5,117
-94% -$12.8K ﹤0.01% 8946
2022
Q4 		$11.4K Buy
5,447
+1,540
+39% +$3.49K ﹤0.01% 8398
2022
Q3 		$8K Buy
3,907
+3,513
+892% +$10.6K ﹤0.01% 8696
2022
Q2 		$1K Sell
394
-2,374
-86% -$8.36K ﹤0.01% 9835
2022
Q1 		$13K Sell
2,768
-7,358
-73% -$40.5K ﹤0.01% 8034
2021
Q4 		$82K Sell
10,126
-6,176
-38% -$60.7K ﹤0.01% 6482
2021
Q3 		$206K Buy
16,302
+1,590
+11% +$22K ﹤0.01% 5289
2021
Q2 		$227K Sell
14,712
-58,458
-80% -$983K ﹤0.01% 5253
2021
Q1 		$1.48M Buy
73,170
+6,050
+9% +$150K ﹤0.01% 3861
2020
Q4 		$1.82M Sell
67,120
-11,446
-15% -$257K ﹤0.01% 3486
2020
Q3 		$1.45M Buy
78,566
+58,884
+299% +$1.04M ﹤0.01% 3360
2020
Q2 		$350K Sell
19,682
-10,738
-35% -$163K ﹤0.01% 4406
2020
Q1 		$280K Buy
30,420
+9,956
+49% +$149K ﹤0.01% 4450
2019
Q4 		$350K Sell
20,464
-12,099
-37% -$162K ﹤0.01% 5155
2019
Q3 		$339K Sell
32,563
-5,347
-14% -$71.9K ﹤0.01% 4851
2019
Q2 		$591K Buy
37,910
+2,284
+6% +$40.8K ﹤0.01% 4169
2019
Q1 		$653K Sell
35,626
-3,473
-9% -$61.6K ﹤0.01% 3875
2018
Q4 		$651K Sell
39,099
-28,220
-42% -$654K ﹤0.01% 4055
2018
Q3 		$1.9M Buy
67,319
+15,997
+31% +$460K ﹤0.01% 3263
2018
Q2 		$1.45M Buy
51,322
+35,939
+234% +$1.07M ﹤0.01% 3451
2018
Q1 		$485K Buy
15,383
+9,054
+143% +$286K ﹤0.01% 4227
2017
Q4 		$185K Sell
6,329
-2,671
-30% -$72.8K ﹤0.01% 4964
2017
Q3 		$257K Buy
9,000
+1,289
+17% +$33.3K ﹤0.01% 4680
2017
Q2 		$200K Sell
7,711
-179
-2% -$4.27K ﹤0.01% 4739
2017
Q1 		$189K Sell
7,890
-38,248
-83% -$804K ﹤0.01% 4681
2016
Q4 		$782K Sell
46,138
-50,766
-52% -$938K ﹤0.01% 3758
2016
Q3 		$2.33M Sell
96,904
-96
-0.1% -$2.51K ﹤0.01% 2706
2016
Q2 		$2.58M Buy
97,000
+4,452
+5% +$131K ﹤0.01% 2562
2016
Q1 		$2.54M Sell
92,548
-6,250
-6% -$151K ﹤0.01% 2453
2015
Q4 		$3.07M Sell
98,798
-14,953
-13% -$454K ﹤0.01% 2404
2015
Q3 		$3M Buy
113,751
+28,471
+33% +$953K ﹤0.01% 2379
2015
Q2 		$3.08M Buy
+85,280
New +$2.99M ﹤0.01% 2563

Other funds holding CLLS

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group's CLLS Position: Q1 2026 in Review

UBS Group reduced its Cellectis (CLLS) stake by 41% in Q1 2026, selling an estimated $77.9K and leaving 29,774 shares worth $94.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7033.

UBS Group first reported a position in CLLS in Q2 2015 and has held it in 40 quarters since. The position peaked at $3.08M in Q2 2015. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

  • UBS Group held 29,774 shares of Cellectis worth $94.4K as of Q1 2026.
  • UBS Group sold 20,326 Cellectis shares in Q1 2026, an estimated $77.9K.
  • Cellectis made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7033 holding.
  • UBS Group first reported a position in Cellectis in Q2 2015 and has held it in 40 quarters since.
  • UBS Group's Cellectis position peaked at $3.08M in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.